

Original article

Iron Deficiency Is a Determinant of Functional Capacity and Health-related Quality of Life 30 Days After an Acute Coronary Syndrome



Oona Meroño,^{a,*} Mercè Cladellas,^a Núria Ribas-Barquet,^a Paula Poveda,^b Lluís Recasens,^a Víctor Bazán,^b Cosme García-García,^b Consol Ivern,^a Cristina Enjuanes,^a Salvador Orient,^c Joan Vila,^d and Josep Comín-Colet^a

^a Departamento de Cardiología, Hospital del Mar, Grupo de Investigación Biomédica en Enfermedades del Corazón, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), Universitat Autònoma de Barcelona, Barcelona, Spain

^b Departamento de Cardiología, Hospital del Mar, Barcelona, Spain

^c Laboratorio de Referencia de Catalunya, El Prat de Llobregat, Barcelona, Spain

^d Grupo de Investigación en Genética y Epidemiología Cardiovascular, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, IMIM (Instituto Hospital del Mar de Investigaciones Médicas)-Hospital del Mar, Barcelona, Spain

Article history:

Received 1 April 2016

Accepted 27 September 2016

Available online 10 November 2016

Keywords:

Iron deficiency
Acute coronary syndrome
Inflammation
Functional capacity
Exercise capacity
Quality of life

ABSTRACT

Background and objectives: Iron deficiency (ID) is a prevalent condition in patients with ischemic heart disease and heart failure. Little is known about the impact of ID on exercise capacity and quality of life (QoL) in the recovery phase after an acute coronary syndrome (ACS).

Methods: Iron status and its impact on exercise capacity and QoL were prospectively evaluated in 244 patients 30 days after the ACS. QoL was assessed by the standard EuroQoL-5 dimensions, EuroQoL visual analogue scale, and Heart-QoL questionnaires. Exercise capacity was analyzed by treadmill/6-minute walk tests. The effect of ID on cardiovascular mortality and readmission rate was also investigated.

Results: A total of 46% of the patients had ID. These patients had lower exercise times (366 ± 162 vs 462 ± 155 seconds; $P < .001$), metabolic consumption rates (7.9 ± 2.9 vs 9.3 ± 2.6 METS; $P = .003$), and EuroQoL-5 dimensions (0.76 ± 0.25 vs 0.84 ± 0.16), visual analogue scale (66 ± 16 vs 72 ± 17), and Heart-QoL (1.9 ± 0.6 vs 2.2 ± 0.6) scores ($P < .05$). ID independently predicted lower exercise times (OR, 2.9; 95%CI, 1.1-7.6; $P = .023$) and worse QoL (OR, 1.9; 95%CI, 1.1-3.3; $P < .001$) but had no effect on cardiovascular morbidity or mortality.

Conclusions: ID, a prevalent condition in ACS patients, results in a poorer mid-term functional recovery, as measured by exercise capacity and QoL.

© 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

El déficit de hierro es un determinante de la capacidad funcional y de la calidad de vida a los 30 días tras un síndrome coronario agudo

RESUMEN

Introducción y objetivos: El déficit de hierro (DH) es una condición frecuente en pacientes con cardiopatía isquémica o insuficiencia cardíaca. Pero se desconoce su impacto en la capacidad funcional y la calidad de vida (CdV) tras un síndrome coronario agudo (SCA).

Métodos: Se evaluó prospectivamente el impacto del DH en la capacidad funcional y la CdV de 244 pacientes 30 días después de haber sufrido un SCA. La CdV se evaluó mediante el test EuroQoL-5 dimensiones, la escala visual analógica y el Heart-QoL. La capacidad funcional se midió mediante ergometría en cinta sin fin o con la prueba de los 6 min de marcha. Se evaluó el impacto del DH en la morbimortalidad cardiovascular.

Resultados: Se documentó DH en el 46% de los pacientes. Estos pacientes realizaban ejercicio menos tiempo (366 ± 162 frente a 462 ± 155 s; $p < 0,001$), presentaban peores tasas metabólicas de consumo ($7,9 \pm 2,9$ frente a $9,3 \pm 2,6$ equivalentes metabólicos; $p = 0,003$) y peor CdV, con puntuaciones más bajas en el EuroQoL-5 dimensiones ($0,76 \pm 0,25$ frente a $0,84 \pm 0,16$), la escala visual analógica (66 ± 16 frente a 72 ± 17) y el Heart-QoL ($1,9 \pm 0,6$ frente a $2,2 \pm 0,6$) (todas, $p < 0,05$). El DH fue un predictor independiente de peor capacidad funcional (OR = 2,9; IC95%, 1,1-7,6; $p = 0,023$) y peor CdV (OR = 1,9; IC95%, 1,1-3,3; $p < 0,001$). No se observó efecto en la morbimortalidad cardiovascular.

Conclusiones: El DH implica peor capacidad funcional y peor calidad de vida a medio plazo tras un SCA.

© 2016 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Palabras clave:

Déficit de hierro
Síndrome coronario agudo
Inflamación
Capacidad funcional
Capacidad de esfuerzo
Calidad de vida

* Corresponding author: Departamento de Cardiología, Hospital del Mar, Paseo Marítimo 25, 08003 Barcelona, Spain.
E-mail address: 98605@parcdesalutmar.cat (O. Meroño).

Abbreviations

ACS: acute coronary syndrome
 CRP: C-reactive protein
 Hb: hemoglobin
 ID: iron deficiency
 IL-6: interleukin-6
 QoL: quality of life

INTRODUCTION

Iron is an essential micronutrient for oxygen transportation and storage, cardiac and skeletal muscle metabolism, and protein synthesis and degradation.¹ In recent years, iron deficiency (ID) has been characterized as a common comorbidity in some cardiovascular diseases and has been associated with worse clinical outcomes and impaired exercise capacity in chronic heart failure.^{2,3} The prognostic impact of ID on heart failure patients is independent of its association with anemia; furthermore, ID reversion with intravenous iron improves functional capacity independently of any increase in hemoglobin (Hb) levels.⁴

Few studies have analyzed the prevalence and clinical determinants of ID in patients with ischemic heart disease, and the available results are focused on its chronic phase.^{5–8} In 1 of these series, ID was associated with increased mortality in patients with stable ischemic heart disease undergoing coronary angioplasty; however, ID was not analyzed separately, as it was always associated with anemia.⁷

To date, the impact of ID on the clinical outcomes of patients presenting with an acute coronary syndrome (ACS) is unknown. We hypothesized that ID precludes adequate mid-term functional recovery after an ACS, as measured by exercise capacity and quality of life (QoL) scores, independently of any association with anemia. For exploratory purposes, we further described the effect of ID on mid-term cardiovascular morbidity and mortality.

METHODS

Study Population and Recruitment

This study was approved by the local ethics committee for clinical research and was conducted according to the principles laid down in the Declaration of Helsinki.

Consecutive patients admitted to our hospital with ACS were prospectively considered for inclusion. All participants gave written informed consent at the time of inclusion. We excluded patients whose ID status could not be determined at day 5 after the ACS and those who were discharged or died before study inclusion. We also excluded patients receiving iron therapy or blood products during hospital admission.

Clinical, biological, echocardiographic, and demographic variables, as well as chronic drug therapy were collected at admission. During hospitalization, the distribution of the coronary artery disease (whenever available) and other therapeutic interventions were also incorporated into the study database.

Analysis of Iron Deficiency

Hb levels were measured on admission. On day 5 after the ACS event, a complete hematological evaluation was undertaken, including repeated Hb levels, mean corpuscular volume, iron

indices (ie, serum ferritin, transferrin, transferrin saturation, and serum iron) and inflammatory parameters (ie, high-sensitivity C-reactive protein [CRP] and interleukin-6 [IL-6]). The decision not to perform these tests in the early acute phase of the ACS was based on the assumption that labile IL-6/CRP levels and the variability and time-dependency of antithrombotic agents administered within the first 48 hours of the ACS would preclude homogeneous characterization of inflammatory and hematological status.

Iron deficiency was defined according to Kidney Disease Outcomes Quality Initiative guidelines as ferritin levels of < 100 ng/mL or as a percentage of transferrin saturation (defined as serum iron ($\mu\text{g/dL}$)/[serum transferrin (mg/dL) \times 1.25]) < 20% when ferritin is < 800 ng/mL.^{9,10} This dual definition takes into account both functional and absolute aspects of ID. Anemia was defined as Hb levels < 13 g/dL (men) or < 12 g/dL (women), according to World Health Organization guidelines.¹¹

Follow-up: Quality of Life and Exercise Capacity Assessment

Patient follow-up at 30 days after the ACS index event took place at the outpatient clinic. The QoL questionnaires and a treadmill exercise test using the Bruce protocol (or, if not feasible, a 6-minute walk test) were administered and the comprehensive hematological evaluation was repeated. The latter 2 tests were omitted as necessary; minimum follow-up consisted of registration of clinical status by telephone.

We used 2 different QoL questionnaires: the generic European QoL-5 dimensions (EQ-5D) plus the visual analogue scale questionnaire and the more specific Heart-QoL test.^{12–14} The EQ-5D questionnaire is a self-reported questionnaire of the patient's health-related QoL in 5 dimensions of daily life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The scoring system in this questionnaire categorizes 5 levels of QoL impairment (no problems, slight problems, moderate problems, severe problems, extreme problems).¹² On the visual analogue scale questionnaire, the patient self-rates his or her health-related QoL status on a 20-cm vertical line. In this study, the reference chosen to contextualize the scores obtained by our study population on this scale was the median value (78 points) of the results of the visual analogue scale questionnaire reported for the overall Spanish population.¹³ The 14-item Heart-QoL questionnaire specifically addresses patients with ischemic heart disease. Patients who report a worse physical and emotional status than their peers also achieve lower Heart-QoL questionnaire scores.¹⁴

Statistical Analysis

For the sample size calculation, we took as a reference previous data analyzing QoL in patients with coronary artery disease and a previous myocardial infarction (a score of 0.80 on the EQ-5D questionnaire) and also considered the prevalence of ID in this population.^{6,15} On the basis of these data, we hypothesized that ACS-ID patients would score 0.75 ± 0.1 on the EQ-5D questionnaire.¹⁵ We admitted an α risk of 0.05 and a β risk of 0.20 in a 2-tailed test, and we estimated a 5% percentage of patients lost to follow-up. As a result, the sample size calculation rendered an estimated sample of 63 cases and 63 controls (total sample size: a minimum of 132 consecutive patients). Further patient inclusion was allowed to provide additional descriptive data regarding the effect of ID on cardiovascular morbidity and mortality.

Data are expressed as mean \pm standard deviation for data with normal distribution and median plus 25–75 percentiles for data with nonnormal distribution. Categorical variables are expressed as frequency and percentage. Clinical differences between the ID and

non-ID groups were analyzed with the Student *t* test, Mann-Whitney *U* test, the chi-square test, or the Fisher exact test as appropriate.

We used a logistic regression model to establish the clinical determinants of ID. A multivariate linear regression model was used to analyze the effect of ID and the other tested variables on exercise capacity. In both models, the clinical determinants of ID reaching a *P* value of $< .10$ in the univariate model were incorporated into a multivariate analysis. Backward modeling was used to assess the independent association between the clinical variables, ID, and exercise capacity. Each variable was removed, one by one, if its exclusion did not significantly modify the likelihood ratio statistics of the model. When removal of any variable changed the estimated parameters of the remaining variables by $> 15\%$, it was considered a confounding effect and the variable was retained in the model regardless of its statistical significance. Calibration was assessed by the Hosmer and Lemeshow test and diagnostic capacity by the area under the receiver operating characteristic curve.

IL-6 and CRP were log transformed (log-IL-6 and log-CRP). To check for linearity, the log-IL-6 was smoothed in a generalized additive model and the *P* value for nonlinear effects was calculated.

A 2-sided *P* value of $< .05$ was considered statistically significant. The statistical analysis was performed with the SPSS 19.0 software package.

RESULTS

Study Population

A total of 789 patients with a diagnosis of ACS were admitted to our hospital from November 2012 through October 2015, of whom 244 were included in our study. The reasons for noninclusion were early transfer to another institution (266 patients) and likelihood of suboptimal mid-term follow-up (261 patients including tourists, individuals with a language barrier, patients with impaired

cognition, and patients who refused to participate). The patient inclusion flowchart is shown in Figure 1.

ID was diagnosed in 139 (57%) patients at day 5, and anemia was diagnosed in 50 of these patients (20% of the total study population). Iron deficiency was significantly associated with old age and most cardiovascular risk factors and comorbidities ($P \leq .01$, except for dyslipidemia and renal disease), as well as with chronic aspirin intake (Table 1). Prior heart failure was underrepresented in our series (only 4 patients), and lacked statistical significance.

We observed no differences in the incidence of hemorrhagic complications between the ID and non-ID groups. Compared with the non-ID group, patients with ID were older, had lower Hb levels, and higher IL-6/CRP levels ($P < .001$; Table 1). A linear correlation between higher IL-6 levels and a higher risk of developing ID was established (*P* value for nonlinear term = .461).

Consistent with our preliminary observation, the multivariate logistic regression model confirmed that higher IL-6 levels (odds ratio [OR], 1.048 per each 1 pg/mL increase; 95% confidence interval [95%CI], 1.013-1.084; $P = .007$) and prior aspirin intake (OR, 3.254; 95%CI, 1.373-7.716; $P = .007$) were independently associated with ID.

Follow-up: Iron deficiency, Exercise Capacity, and Quality of Life

ID persisted in 102 (46%) of the 226 ACS patients tested at day 30; follow-up was limited in the remaining 18 patients (Figure 1). At this mid-term follow-up, the ID group still had lower Hb levels than the non-ID group ($P < .01$). Only 1 of the 244 patients was lost during follow-up and 5 patients did not participate in any part of the 30-day follow-up visit due to death or hospital readmission (Figure 1). Overall, there had been 7 major acute cardiovascular events at day 30, including 2 deaths and 5 hospital readmissions (4 due to heart failure and 1 due to myocardial reinfarction). This low incidence of major acute cardiovascular events precluded




Figure 1. Study flowchart of patient inclusion. ACS, acute coronary syndrome.

Table 1
Clinical Characteristics of Patients With and Without Iron Deficiency

	Non-ID (n = 105)	ID group (n = 139)	P
Sex, male, n (%)	87 (83)	92 (66)	.002
Age (SD) y	61 (12)	67 (15)	.002
Cardiovascular risk factors			
Diabetes, n (%)	20 (19)	48 (35)	.005
Hypertension, n (%)	51 (49)	106 (76)	< .001
Dyslipidemia, n (%)	55 (52)	80 (58)	.250
Smoking, n (%)	52 (49)	34 (25)	< .001
Comorbidities			
Previous ischemic heart disease, n (%)	20 (19)	35 (25)	.164
Previous heart failure, n (%)	1 (1)	4 (3)	.284
COPD, n (%)	6 (6)	22 (16)	.010
Anemia, n (%)	2 (2)	13 (9)	.014
Renal disease,* n (%)	7 (7)	16 (12)	.141
Chronic treatment			
Aspirin, n (%)	18 (17)	51 (37)	< .001
Other antiplatelet drugs, n (%)	3 (3)	6 (4)	.406
Anticoagulants, n (%)	6 (6)	8 (6)	.608
Beta-blockers, n (%)	18 (17)	32 (23)	.167
ACE inhibitor, n (%)	28 (27)	50 (36)	.080
Statins, n (%)	39 (37)	58 (42)	.277
Clinical parameters			
STEMI, n (%)	63 (60)	70 (50)	.086
Heart rate, mean (SD), bpm	73 (16)	76 (18)	.153
SBP at admission, mean (SD), mmHg	135 (26)	139 (31)	.299
Glucose at admission, mean (SD), mg/dL	136 (49)	160 (15)	.003
Hemoglobin at admission, mean (SD), g/dL	14.6 (1.5)	13.7 (1.9)	< .001
Creatinine at admission, mean (SD), mg/dL	1.1 (1)	1.1 (0.9)	.731
Maximum hs-TnT level, median (p:25-p:75)	1038 (288-3302)	1259 (271-4691)	.662
LVEF, mean (SD),%	56 (9)	54 (11)	.168
Killip II-IV, n (%)	10 (10)	18 (13)	.256
Procedures performed			
Blood extraction, n test during admission, mean (SD)	6.0 (2)	6.5 (2)	.057
Coronary angiography, n (%)	94 (90)	123 (89)	.840
Left main disease, n (%)	7 (6)	5 (4)	.384
Multivessel disease, n (%)	36 (34)	49 (35)	.783
Angioplasty, n (%)	86 (82)	99 (71)	.070
Treatment received during admission			
Aspirin, n (%)	103 (98)	136 (98)	1
Other antiplatelet drugs, n (%)	104 (99)	139 (100)	.430
Low molecular heparin, n (%)	77 (73)	112 (81)	.216
Oral anticoagulants, n (%)	5 (5)	9 (7)	.782
Beta-blockers, n (%)	93 (87)	135 (97)	.009
ACE inhibitor, n (%)	89 (85)	106 (76)	.109
Statins, n (%)	105 (100)	139 (100)	
Iron status measured at day 5			
Hemoglobin, mean (SD), g/dL	14.7 (1.4)	13.2 (1.5)	< .001
Iron, mean (SD), mcg/dL	82 (24)	49 (19)	< .001
Ferritin, median (p:25-p:75), ng/mL	258 (174-392)	127 (62-282)	< .001
% Transferrin saturation, mean (SD)	29 (10)	16 (6)	< .001
Inflammatory status measured at day 5			
hs-CRP, median (p:25-p:75), mg/dL	0.9 (0.4-1.7)	1.8 (0.8-4.1)	< .001
IL-6, median (p:25-p:75), pg/mL	5.9 (3.8-9.4)	11.1 (6.4-17.3)	< .001

ACE inhibitor, angiotensin-converting enzyme inhibitor; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-sensitivity troponin T; ID, iron deficiency; IL-6, interleukin-6; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction.

* Glomerular filtration < 60 mL/min/1.73m².




Figure 2. Exercise time achieved by the ID and non-ID patient groups. Within each box, the middle horizontal line corresponds to the median, the lower limit to the first quartile, and the upper limit to the third quartile. The whiskers represent the 95% confidence interval of the mean. ID, iron deficiency.

assessment of significant differences between groups, with no preliminary differences between the ID and non-ID groups in our series.

Iron Deficiency and Exercise Capacity

Sixty (27%) of the 226 patients did not undergo any exercise tests, due to severe osteoarthritis, peripheral artery disease, loss of balance, and/or suboptimal adaptation to the treadmill. Of the remaining patients (Figure 1), 153 completed the treadmill test and 13 did the 6-minute walk test instead. Iron deficiency was 41%

in this group and 66% in those who could not perform any exercise test ($P < .001$). In the treadmill group, patients with persistent ID at day 30 had lower exercise capacity, as measured by total exercise time and a lower rate of metabolic consumption than those without ID at follow-up (7.9 ± 2.9 vs 9.3 ± 2.6 METS; $P = .003$ and 366 ± 162 vs 462 ± 155 seconds; $P < .001$, respectively) (Figure 2). These differences were not influenced by the proportion of patients with and without ID who were taking beta-blockers (93% vs 92% respectively; $P = .80$). Patients with ID who did the 6-minute walk test also walked a shorter distance than patients without ID (277 vs 423 meters respectively; $P = .009$). When adjusted for other comorbidities, ID was significantly associated with a lower exercise capacity in the multivariate linear regression model ($P = .008$), as were older age, diabetes, chronic pulmonary disease, and low left ventricular ejection fraction (Table 2). Importantly, the association between ID and lower exercise capacity was accompanied by a significant increase in the R^2 coefficient in this multivariate regression model (from 0.510 to 0.538) and it remained statistically significant when nonanemic patients were independently analyzed ($P = .048$; Table 2).

Similarly, when exercise capacity was analyzed as a binary variable, and with the median exercise time (418 seconds) being taken as the reference, most patients with ID had exercise times below this median value and ID was associated with impaired functional capacity (ie, exercise time < 418 seconds) in both the univariate (OR, 2.8; 95%CI, 1.4-5.5; $P = .004$) and the multivariate (OR, 2.9; 95%CI, 1.1-7.6; $P = .023$) analyses.

Iron Deficiency and Quality of Life

A total of 226 patients underwent blood testing and completed the QoL questionnaires at day 30. The ID group had lower scores than the non-ID group on the EQ-5D questionnaire ($P = .005$), visual analogue scale questionnaire ($P = .008$), and Heart-QoL questionnaires ($P = .004$) (Table 3). Iron deficiency mainly influenced the ‘mobility’ and ‘usual activities’ domains in the EQ-5D

Table 2

Exercise Capacity on Treadmill Test. Univariate and Multivariate Linear Regression Models for the Analysis of Demographics and Clinical Factors Related to Exercise in all Patients and in Nonanemic Patients

Models	Univariate						Multivariate (backward methods)			
	All patients (n = 153)			Nonanemic (n = 139)			All patients (n = 153)		Nonanemic (n = 139)	
Exercise time (sec)	β Sc*	R ²	P	β Sc*	R ²	P	β Sc*	P	β Sc*	P
Age, 1 y	-0.585	0.338	< .001	-0.550	0.303	< .001	-0.524	< .001	-0.479	< .001
Sex, female/male	-0.206	0.042	.011	-0.213	0.046	.012	-	-	-	-
Diabetes, yes/no	-0.307	0.094	< .001	-0.334	0.111	< .001	-0.165	.010	-0.221	.002
Hypertension, yes/no	-0.221	0.049	.006	-0.195	0.038	.022	-	-	-	-
COPD, yes/no	-0.341	0.016	< .001	-0.329	0.109	< .001	-0.176	.006	-0.171	.014
PVD, yes/no	-0.149	0.022	.067	-0.089	0.008	.312	-	-	-	-
STEACS, yes/no	-0.023	0.001	.774	-0.074	0.005	.386	-	-	-	-
Smoking, yes/no	0.191	0.036	.018	0.174	0.030	.041	-	-	-	-
Maximum hs-TnT level, 1 ng/L	-0.084	0.007	.343	-0.107	0.012	.251	-	-	-	-
LVEF, 1 point (%)	0.213	0.045	.013	0.189	0.036	.038	0.182	.003	0.187	.007
Angioplasty performed, yes/no	-0.013	0.000	.878	0.000	0.000	.996	-	-	-	-
Testosterone, 1 ng/mL	0.085	0.007	.338	0.092	0.009	.323	-	-	-	-
Hemoglobin at 30 days, 1 g/dL	0.345	0.113	< .001	0.243	0.059	.004	-	-	-	-
ID at 30 days, yes/no	-0.283	0.080	< .001	-0.201	0.040	.018	-0.169	.008	-0.138	.042
Adjusted R ² for each model							.538		.508	

COPD, chronic obstructive pulmonary disease; GF, glomerular filtration; hs-TnT level, high-sensitivity troponin T; ID, iron deficiency; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease; STEACS, ST-segment elevation acute coronary syndrome.

* β Sc, β Standardized coefficients. Statistical significance was set at $P < .05$.

Table 3
Quality of Life at 30 Days

	Non-ID group (n = 124)	ID group (n = 102)	P
VAS, points (SD)	72 (17)	66 (16)	.008
EQ-5D index (SD)	0.84 (0.16)	0.76 (0.25)	.005
<i>Patients reporting problems (EQ-5D)</i>			
Usual activities, n (%)	41 (33)	50 (49)	.011
Mobility, n (%)	36 (29)	53 (52)	< .001
Anxiety/depression, n (%)	64 (52)	62 (61)	.180
Pain/discomfort, n (%)	61 (49)	51 (50)	1
Self-care	15 (15)	20 (20)	.372
<i>Heart-QoL global coefficient (SD)</i>	2.2 (0.6)	1.9 (0.6)	.004
<i>Heart-QoL physical coefficient (SD)</i>	2.2 (0.7)	1.9 (0.7)	.004
<i>Heart-QoL emotional coefficient (SD)</i>	2.3 (0.6)	2.1 (0.7)	.034

EQ-5D, European quality of life-5 dimensions questionnaire; Heart-QoL, heart disease health-related quality of life questionnaire; ID, iron deficiency; SD, standard deviation; VAS, visual analogue scale.

Values are expressed as mean (SD) or n (%).

Statistical significance was set at $P < .05$.

questionnaire. On the visual analogue scale questionnaire, 75% of the ID group scored below the preliminary 78-point cutoff value compared with 49% of the non-ID group ($P < .001$). Similarly, 60% of the patients with ID scored below the median value (2.21 points) in the Heart-QoL questionnaire, compared with only 42% of the non-ID group ($P = .009$). After adjustment by age, sex, anemia, chronic obstructive pulmonary disease, renal failure, hypertension, and diabetes, ID remained an independent predictor of impaired QoL according to the visual analogue scale questionnaire (OR, 3.021; 95%CI, 1.672–5.457; $P < .001$) and Heart-QoL questionnaires (OR, 1.9; 95%CI, 1.079–3.348; $P < .001$).

DISCUSSION

Major Findings

The present study identified ID as a major determinant of impaired functional capacity ($P < .01$) and QoL ($P < .01$) after an ACS, independently of the presence or absence of anemia. Our study defines ID as a highly prevalent underlying comorbidity in the setting of an ACS that could constitute a potential pharmacological target to support functional recovery after the ACS index event. In this regard, the role of iron repletion deserves further investigation. The very low death and reinfarction rates observed in our series precluded confirmation of ID as a clinical predictor of major cardiovascular morbidity and mortality after an ACS.

Pathophysiological Aspects

The definition of ID originally derives from reported series of patients with chronic kidney disease, who frequently have an indication for iron repletion. Recently, ID has been characterized in other chronic diseases, such as rheumatoid arthritis and other inflammatory diseases, heart failure, and ischemic heart disease.

Identification of ID is challenging in the pathological processes that are accompanied by inflammation, such as an ACS. In this scenario, ID is suggested when ferritin and/or the serum iron levels (which have a controversial prognostic impact in a number of cardiovascular diseases) are not used as the sole criterion; the

definition of ID also includes the degree of transferrin saturation ('multi-marker' definition).^{9,10,16–19}

ID is a highly prevalent condition in patients with cardiovascular disease, especially in stable and acute coronary artery disease and chronic heart failure.^{5,6,20–23} There is no clear evidence on the mechanisms involved in the development of ID in cardiac patients. The present study corroborated an earlier report that chronic use of aspirin and proinflammatory status (as demonstrated by increased CRP/IL-6 levels) are independent determinants of ID in ACS patients.⁶ Chronic gastrointestinal bleeding and common upstream inflammatory pathways shared by coronary artery disease (and specifically its destabilization) and the ID pathological process, respectively, may account for such associations.^{16,24,25} Proinflammatory status reduces both the absorption/availability of iron (ID) and participates in the 'destabilization' of the coronary atherosclerotic plaque causing the ACS event.^{26–34}

Iron Deficiency, Functional Capacity, and Quality of Life

ID entails a decreased oxidative capacity of the skeletal muscle and an increased reliance on carbohydrates as the substrate for energy, thereby causing impaired endurance. This principle is independent of the association between ID and anemia.^{35,36} The presence of ID has been associated with worse physical performance and lower oxygen uptake (VO_2 max consumption) in both young athletes and sedentary women without anemia.^{37–39} In addition, in heart failure patients, ID produces impaired exercise capacity.² Our findings indicate that ID also jeopardizes aerobic work capacity in the mid-term after an ACS. Interestingly, low Hb levels were not independently associated with ID in the multivariate analyses (data not shown) and ID was also associated with a decreased exercise capacity in patients who were not anemic. These observations emphasize the primary role of ID in the patient's functional recovery after the ACS event, beyond the association with anemia.

In the present study, patients with ID reported poorer QoL, essentially linked to perceived limitations in mobility and physical activity capacities. Functional impairments drive important effects of self-perceived health status.^{17,40} In light of our results, this assumption can also be extrapolated to the clinical setting of the mid-term recovery phase after an ACS.

Iron Deficiency: A Therapeutic Target After an Acute Coronary Syndrome?

Many nonmodifiable factors such as sex, age, education, and marital/occupational status may affect self-perceived functional capacity and QoL.⁴¹ The identification of a potentially modifiable variable such as ID might provide a pharmacological target in the search for optimal functional recovery after an ACS event. Correction of ID improves both QoL and exercise performance in heart failure patients.^{42,40,43} Determining whether ID reversion will drive a significant mid-term improvement in QoL and exercise capacity after an ACS will require further investigation.

Study Limitations

Because ID and inflammatory parameters were assessed on day 5 after the ACS, patients who died in the acute phase of the ACS were not represented in this study, thus constituting a potential selection bias. The decision to delay iron/inflammatory status determination was made to prevent the results from being influenced by hypoxia time, ischemia-reperfusion phenomenon, and the antithrombotic treatment administered during the initial phases of the ACS.⁴⁴

The standardized beta coefficient featuring the impact of ID on the patient's functional recovery, although consistent with that reported in heart failure patients, has to be considered somewhat low.^{3,21} Similarly, the R^2 value of 0.54, although higher than that reported in patients with heart failure and ID, could be considered somewhat modest.^{21,45}

The significant number of patients who declined to participate or were excluded due to mid-term follow-up concerns (261 patients) may jeopardize the representativeness of the study sample. In addition, no exercise test could be performed due to mobility problems in one fourth of our patients. We consider this limitation a natural consequence of the phenomenon of progressive aging of ACS patients in the western countries.

The present study lacks statistical power to demonstrate a prognostic effect of ID on cardiovascular outcome after an ACS. Data regarding cardiovascular morbidity and mortality are provided in this study for descriptive and exploratory purposes only.

CONCLUSIONS

ID is a highly prevalent underlying condition in the ACS setting, and persists in the mid-term. The persistence of ID significantly compromises the exercise capacity and the QoL of ACS patients, independently of any association with anemia. Given its potential reversion by means of iron repletion, ID may offer a pharmacological target in ACS patients, which could support optimal functional recovery after a coronary event. The long-term impact of ID (and its treatment) on major cardiovascular mortality and morbidity in this setting is yet to be determined.

ACKNOWLEDGMENTS

Research reported in this publication was supported by the Catalan Society of Cardiology under a Servier award 2012.

CONFLICTS OF INTEREST

J. Comín-Colet was a member of the FAIR-HF steering committee and the CONFIRM-HF trial (sponsored both by Vifor Pharma Ltd.), and has received honoraria for speaking

from Vifor Pharma Ltd. All other authors have no conflicts to declare.

WHAT IS KNOWN ABOUT THE TOPIC?

- ID is a highly prevalent underlying condition in ACS patients.
- Prior use of aspirin, low Hb levels, and proinflammatory status are associated with the development of ID in these patients.
- Little is known about the influence of ID on patients' clinical and functional outcome after an ACS, since this prognostic information has not been previously reported.

WHAT DOES THIS STUDY ADD?

- Our study revealed that ID is associated with both impaired functional capacity and lower QoL in ACS patients, regardless of the presence or absence of anemia.
- Given its potential reversion by means of iron repletion, ID might constitute a pharmacological target in this clinical scenario.

REFERENCES

1. Assessing the iron status of population. Report of a Joint World Health Organization/Centers for Disease Control and Prevention Technical Consultation on the Assessment of Iron Status at the Population Level. 2nd ed. Geneva, Switzerland; 2004. p. 3-5.
2. Enjuanes C, Bruguera J, Grau M, et al. Iron status in chronic heart failure: impact on symptoms, functional class and submaximal exercise capacity. *Rev Esp Cardiol*. 2016;69:247–255.
3. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. *J Card Fail*. 2011;17:899–906.
4. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J*. 2015;36:657–668.
5. Jankowska EA, Wojtas K, Kasztura M, et al. Bone marrow iron depletion is common in patients with coronary artery disease. *Int J Cardiol*. 2015;182:517–522.
6. Meroño O, Cladellas M, Ribas N, Recasens L, Bazan V, Comin J. Déficit de hierro en pacientes con síndrome coronario agudo: prevalencia y factores predisponentes. *Rev Esp Cardiol*. 2016;69:615–617.
7. Varma A, Appleton DL, Nusca A, et al. Iron deficiency anemia and cardiac mortality in patients with left ventricular systolic dysfunction undergoing coronary stenting. *Minerva Cardioangiol*. 2010;58:1–10.
8. Ponikowska B, Suchocki T, Paleczny B, et al. Iron status and survival in diabetic patients with coronary artery disease. *Diabetes Care*. 2013;36:4147–4156.
9. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. *KDOQI. Am J Kidney Dis*. 2007;50:471–530.
10. Rimon E, Levy S, Sapir A, et al. Diagnosis of iron deficiency anemia in the elderly by transferrin receptor-ferritin index. *Arch Intern Med*. 2002;162:445–449.
11. Report of a WHO scientific group. Nutritional anaemias. *World Health Organ Tech Rep Ser*. 1968;405:5–37.
12. Nowels D, McGloin J, Westfall JM, Holcomb S. Validation of the EQ-5D quality of life instrument in patients after myocardial infarction. *Qual Life Res*. 2005;14:95–105.
13. La Encuesta Nacional de Salud de España 2011/12 (ENSE 2011/12). Ministerio de Sanidad, Servicios Sociales e Igualdad [accessed 27 Sept, 2016] http://www.msssi.gob.es/estadEstudios/estadisticas/encuestaNacional/encuestaNac2011/informesMonograficos/CVRS_adultos_EQ_5D_5L.pdf.
14. Oldridge N, Höfer S, McGee H, Conroy R, Doyle F, Saner H. The HeartQoL: part II. Validation of a new core health-related quality of life questionnaire for patients with ischemic heart disease. *Eur J Prev Cardiol*. 2014;21:98–106.
15. Pettersen K, Kvan I, Rollag A, Stavem K, Reikvam A. Health-related quality of life after myocardial infarction is associated with level of left ventricular ejection fraction. *BMC Cardiovascular Disorders*. 2008;8:28.

16. Huang CH, Chang CC, Kuo CL, et al. Serum iron concentration, but not hemoglobin, correlates with TIMI risk score and 6-month left ventricular performance after primary angioplasty for acute myocardial infarction. *PLoS One*. 2014;9:e104495.
17. Steen DL, Cannon CP, Lele SS, et al. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. *Clin Cardiol*. 2013;36:139–145.
18. Dale JC, Burritt MF, Zinsmeister AR. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. *Am J Clin Pathol*. 2002;117:802–808.
19. Bogniard RP, Whipple GH. The iron content of blood free tissues and viscera: variations due to diet, anemia and hemoglobin injections. *J Exp Med*. 1932;55:653–665.
20. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. *Am Heart J*. 2013;165:575–582.
21. Comin-Colet J, Enjuanes C, González G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. *J Eur J Heart Fail*. 2013;15:1164–1172.
22. Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. *Int J Cardiol*. 2014;174:268–275.
23. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. *Eur Heart J*. 2010;31:1872–1880.
24. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. *Int J Cardiol*. 2006;109:248–256.
25. Meroño O, Cladellas M, Recasens L, et al. Acquired anemia in acute coronary syndrome. Predictors, in-hospital prognosis and one-year mortality. *Rev Esp Cardiol*. 2012;65:742–748.
26. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. *Blood*. 2009;113:5277–5286.
27. Piperno A, Galimberti S, Mariani R, et al. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo. *Blood*. 2011;117:2953–2959.
28. Martínez-Ruiz A, Tornel-Osorio PL, Sánchez-Más J, et al. Soluble TNF α receptor type I and hepcidin as determinants of development of anemia in the long-term follow-up of heart failure patients. *Clin Biochem*. 2012;45:1455–1458.
29. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). *Circulation*. 2001;103:2055–2059.
30. Luo Y, Jiang D, Wen D, Yang J, Li L. Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin. *Heart Vessels*. 2004;19:257–262.
31. Biassuci L, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. *Circulation*. 1996;94:874–877.
32. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. *Circulation*. 2000;101:1372–1378.
33. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation*. 2000;101:1767–1772.
34. Brunetti ND, Correale M, Pellegrino PL, et al. Early inflammatory cytokine response: a direct comparison between spontaneous coronary plaque destabilization vs angioplasty induced. *Atherosclerosis*. 2014;236:456–460.
35. Person R, Seiler K, Mackler B. Iron deficiency in the rat: physiological and biochemical studies of muscle dysfunction. *J Clin Invest*. 1976;58:447–453.
36. Davies K, Donovan M, Refino C, Brook G, Packer L, Dallman P. Distinguishing effects of anemia and muscle iron deficiency on exercise bioenergetics in rats. *Am J Physiol*. 1984;246:535–543.
37. Newhouse IJ, Clement DB. Iron status in athletes. *An update Sports Med*. 1988;5:337–352.
38. Zhu YI, Haas JD. Iron depletion without anemia and physical performance in young women. *Am J Clin Nutr*. 1997;66:334–341.
39. Brownlie T, Utermohlen V, Hinton PS, Giordano C, Haas JD. Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. *Am J Clin Nutr*. 2002;75:734–742.
40. Gutzwiller FS, Pfeil AM, Comin-Colet J, et al. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. *Int J Cardiol*. 2013;168:3878–3883.
41. Yaghoubi A, Tabrizi JS, Mirinazhad MM, Azami S, Naghavi-Behzad M, Ghajzadeh M. Quality of life in cardiovascular patients in Iran and factors affecting it: a systematic review. *J Cardiovasc Thorac Res*. 2012;4:95–101.
42. Lord SR, Menz HB. Physiologic, psychologic, and health predictors of 6-minute walk performance in older people. *Arch Phys Med Rehabil*. 2002;83:907–911.
43. Anker SD, Colet JC, Filippatos G, et al. For the FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med*. 2009;361:2436–2448.
44. Loubele ST, Spek CA, Leenders P, et al. Activated protein C protects against myocardial ischemia/reperfusion injury via inhibition of apoptosis and inflammation. *Arterioscler Thromb Vasc Biol*. 2009;29:1087–1092.
45. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. *J Card Fail*. 2011;17:899–906.